ARTICLE | Company News

Celgene other research news

December 11, 2000 8:00 AM UTC

Under a 5-year CRADA with the National Cancer Institute, CELG will develop its oral small molecule SelCID compounds, which inhibit phosphodiesterase IV (PDE4) and prevent overproduction of TNF-alpha. The CRADA will include preclinical testing to assess the compounds' antiangiogenic and anti-tumor activity as well as Phase I and Phase II studies of lead SelCID compounds. CELG's CDC-801 SelCID is in separate Phase II testing to treat Crohn's disease. ...